Mark Ragosa: Yes, I guess to your question regarding our thinking on capital, I mean, we think we’re very well capitalized. As I mentioned, $201 million in reserves at the end of the third quarter. At the end of the day, our runway, which we guided to having cash in at least 2027 the ultimate time line depends upon the success of our current and future investments and sort of any future investments that are spawned from the original investment. So we feel very confident in our runway in our cash reserve base of $201 million at the end of the quarter.
Unidentified Analyst: Great. Thanks.
Operator: Thank you. Our next question will come from Liisa Bayko of Evercore ISI. Your line is open.
Liisa Bayko: Hi, thanks for taking the question. Can you maybe quantitate a little bit more the amount of inventory changes that you’re seeing and how that’s contributing to kind of I guess, what seems like a flat quarter-over-quarter into the fourth quarter, but I know this is offset by some inventory changes. So, if you could quantify that would be helpful. Thank you.
Ross Moat: Yes, that’s right. In some of that is, this is Ross. So, maybe I’ll go through that in a little way. I mean we continue to see robust performance across all the key drivers of the commercialization. And as I said, we believe we’ve still got a huge potential ahead. But when we look at the growth that we had in Q4 and thinking forward to the end of the year, to be very clear, we expect continued growth in Q4 despite a couple of expected headwinds and those being firstly, related to some pressure on our gross to net in Q4 and that’s driven from a couple of things. Firstly, from end-of-year accounting for insurance resets and increases the co-pay systems. So, they’re really kind of industry-wide items in specialty medicine, but as well as changes that we’ve had to our specialty pharmacy network, which may drive a slightly higher gross to net in Q4.
And secondly, we’re expecting inventory to level out in Q4 following some of the favorability we had in that regard under the prior quarter so we expect some additional pressure to the magnitude of the Q4 revenue growth, but certainly still expecting revenue growth in Q4. And as we said, they are tracked into the high end of the guidance we provided.
Liisa Bayko: Great. Can you just quantitate the inventory change a little bit more, like what amount are we talking about? And then also what we’re closing that in the third quarter? Thanks.
Ross Moat: Yes. So, we haven’t really quantified the inventory amount, but what we have said is that the majority — the vast majority of the growth comes down to having a higher number of patients on therapy has really been the key driver of all of our quarters worth of growth since the time of launch. So, that’s the vast majority and then to a smaller level, there’s a little bit of inventory dynamic there, as we’ve mentioned. Gross to net year-to-date is 9.9% and that’s versus 9% in 2022. So, there’s always some quarterly fluctuations, but that’s where we are at 9.9% so far this year.
Liisa Bayko: Thank you.
Operator: Thank you. I am seeing no further questions in the queue. I would now like to turn the conference back to Sanj Patel for closing remarks.
Sanj Patel: Thank you very much for the questions and joining the call today. We clearly have an exciting time ahead of us and very much looking forward to providing additional updates in the future. So, until then, thanks very much.
Operator: This concludes today’s conference call. Thank you all for participating. You may now disconnect and have a pleasant day.
